Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan

Figures & data

Table 1. Anti-MuV IgG antibody titer and seropositivity against MuV infection regarding medical history, vaccination number and elapsed period after last vaccination

Item	Anti-MuV IgG antibody titer (mean±standard error)	Significance	Seropositive/Total number	Seropositivity %
Total	7.7 ± 0.6	NS	261/409	64
Femal	7.7 ± 0.7		104/159	65
Male	7.7 ± 0.9		157/250	63
Medical history
Yes	10.1 ± 1.2	**	138/155	89
No	6.3 ± 0.6		123/254	48
Vaccination number^a
0	7.3 ± 0.7	**	58/100	58
1	7.1 ± 0.7		69/137	50
2	19.0 ± 7.0		11/17	65
Elapsed period after last vaccination^b
<10 year	11.9 ± 3.0	**	27/37	73
≥10 year	4.5 ± 0.3		38/89	43

^aThe participants with mumps medical history were excluded.

^bThe participants who were not received mumps vaccine or those were received mumps vaccine within one month or those with mumps medical history were excluded.

NS: Not significance

**P < 0.01